ABBV analyst estimates
AbbVie (ABBV) analyst ratings, the average price target and its range, and every firm's latest call.
ABBV analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 23, 2026 | Goldman Sachs | AbbVie price target raised to $294 from $258 at Goldman Sachs | $294.00 |
| Oct 21, 2026 | Barclays | AbbVie price target raised to $325 from $300 at Barclays | $325.00 |
| Oct 8, 2026 | Cantor Fitzgerald | Abbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald | $290.00 |
| Oct 7, 2026 | Morgan Stanley | AbbVie price target raised to $310 from $296 at Morgan Stanley | $310.00 |
| Oct 6, 2026 | Scotiabank | AbbVie price target raised to $320 from $280 at Scotiabank | $320.00 |
| Sep 10, 2026 | HSBC | AbbVie price target raised to $315 from $300 at HSBC | $315.00 |
| Aug 20, 2026 | Piper Sandler | AbbVie price target raised to $303 from $298 at Piper Sandler | $303.00 |
| Aug 17, 2026 | Wells Fargo | AbbVie price target raised to $300 from $295 at Wells Fargo | $300.00 |
| Aug 13, 2026 | Wolfe Research | AbbVie upgraded to Outperform from Peer Perform at Wolfe Research | $300.00 |
| Aug 4, 2026 | Guggenheim | AbbVie price target raised to $288 from $261 at Guggenheim | $288.00 |
| Aug 3, 2026 | Canaccord Genuity | Abbvie (ABBV) PT Raised to $290 at Canaccord | $290.00 |
| Aug 3, 2026 | Morgan Stanley | AbbVie price target raised to $296 from $278 at Morgan Stanley | $296.00 |
| Jul 29, 2026 | Barclays | AbbVie price target raised to $300 from $275 at Barclays | $300.00 |
| Jul 22, 2026 | Canaccord Genuity | AbbVie price target raised to $282 from $273 at Canaccord | $282.00 |
| Jul 13, 2026 | UBS | AbbVie price target raised to $260 from $230 at UBS | $260.00 |
- 19 firms rate ABBV: 15 buy, 4 hold, 0 sell.
- The average price target is $299.58 from 12 analysts, from $260.00 to $325.00.
Updated 2026-11-02 17:52 UTC